GlassScriptPhysician profile
Farra M Wilson
NPI 1659667210
$5,178.25
in general payments reported to CMS, 2019-2025
36 companies · $770 in 2025
The $770 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $167 · 2021: $211 · 2022: $673 · 2023: $1,090 · 2024: $1,232 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,986 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,985.99 |
| Education | $106.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,879.03 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Pfizer INC. | $358.29 | 2019-2025 | |
| Janssen Biotech, INC. | $247.21 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $230.85 | 2022-2024 | Zeposia |
| Steris Corporation | $216.55 | 2022 | |
| Gilead Sciences, INC. | $211.40 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $182.36 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $167.97 | 2019-2025 | Eohilia, Entyvio |
| Allergan, INC. | $148.18 | 2019 | |
| Janssen Scientific Affairs, LLC | $147.39 | 2024 | Tremfya |
| Enterra Medical, INC. | $144.15 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.48 | 2019-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $82.40 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $80.92 | 2023 | Rebyota |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $80.38 | 2023-2024 | Idacio |
| Merck Sharp & Dohme LLC | $77.06 | 2023 | Dificid |
| Ironwood Pharmaceuticals, INC | $76.03 | 2022-2024 | Linzess |
| Echosens North America, INC. | $67.16 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $62.78 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $51.12 | 2024-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $50.83 | 2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $50.76 | 2021-2023 | |
| Ardelyx, INC. | $50.64 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $40.78 | 2019-2022 | |
| Amgen INC. | $38.69 | 2021-2023 | Avsola, Amjevita |
| Intercept Pharmaceuticals, INC. | $32.58 | 2019 | |
| Organon LLC | $25.86 | 2023 | Renflexis |
| Alnylam Pharmaceuticals INC. | $24.65 | 2024 | Givlaari |
| Genzyme Corporation | $24.20 | 2023 | |
| Sandoz INC. | $21.40 | 2024 | Hyrimoz |
| Redhill Biopharma INC. | $17.93 | 2023 | Talicia, Aemcolo, Movantik |
| Janssen Pharmaceuticals, INC | $14.61 | 2019 | |
| Pentax of America, INC. | $13.91 | 2020 | |
| Ucb, INC. | $13.08 | 2019 | |
| Dynavax Technologies Corporation | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farra Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.